JP2019531254A - Ｐｒｌ３抗体 - Google Patents

Ｐｒｌ３抗体 Download PDF

Info

Publication number
JP2019531254A
JP2019531254A JP2018565319A JP2018565319A JP2019531254A JP 2019531254 A JP2019531254 A JP 2019531254A JP 2018565319 A JP2018565319 A JP 2018565319A JP 2018565319 A JP2018565319 A JP 2018565319A JP 2019531254 A JP2019531254 A JP 2019531254A
Authority
JP
Japan
Prior art keywords
antibody
prl3
prl
cancer
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018565319A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531254A5 (enExample
Inventor
ザン，チー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of JP2019531254A publication Critical patent/JP2019531254A/ja
Publication of JP2019531254A5 publication Critical patent/JP2019531254A5/ja
Priority to JP2022033194A priority Critical patent/JP7408707B2/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018565319A 2016-06-14 2017-06-14 Ｐｒｌ３抗体 Pending JP2019531254A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022033194A JP7408707B2 (ja) 2016-06-14 2022-03-04 Ｐｒｌ３抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201604834P 2016-06-14
SG10201604834P 2016-06-14
PCT/SG2017/050300 WO2017217934A1 (en) 2016-06-14 2017-06-14 Prl3 antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022033194A Division JP7408707B2 (ja) 2016-06-14 2022-03-04 Ｐｒｌ３抗体

Publications (2)

Publication Number Publication Date
JP2019531254A true JP2019531254A (ja) 2019-10-31
JP2019531254A5 JP2019531254A5 (enExample) 2020-06-18

Family

ID=60663634

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018565319A Pending JP2019531254A (ja) 2016-06-14 2017-06-14 Ｐｒｌ３抗体
JP2022033194A Active JP7408707B2 (ja) 2016-06-14 2022-03-04 Ｐｒｌ３抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022033194A Active JP7408707B2 (ja) 2016-06-14 2022-03-04 Ｐｒｌ３抗体

Country Status (10)

Country Link
US (1) US11155636B2 (enExample)
EP (1) EP3469003A4 (enExample)
JP (2) JP2019531254A (enExample)
KR (1) KR102451588B1 (enExample)
CN (1) CN109476759B (enExample)
AU (1) AU2017285995B2 (enExample)
BR (1) BR112018075901A2 (enExample)
CA (1) CA3025756A1 (enExample)
SG (1) SG11201811068YA (enExample)
WO (1) WO2017217934A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023219091A1 (ja) 2022-05-11 2023-11-16 国立研究開発法人産業技術総合研究所 アンモニア分離膜及びそれを用いたアンモニア分離方法
WO2025116819A1 (en) * 2023-11-30 2025-06-05 Agency For Science, Technology And Research Methods of treating neovascular eye diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008518619A (ja) * 2004-11-08 2008-06-05 エピトミクス インコーポレーティッド 抗体エンジニアリングのための方法
JP2010530735A (ja) * 2007-05-03 2010-09-16 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 細胞内のｐｒｌ−１ポリペプチドまたはｐｒｌ−３ポリペプチドに結合する抗体
JP2012505654A (ja) * 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
WO2015119570A1 (en) * 2014-02-07 2015-08-13 Agency For Science, Technology And Research Prl-3 as a biomarker for the prognosis of cancer and a target for therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287644A1 (en) * 2004-05-14 2005-12-29 Genesis Biotech Inc. Methods for producing and culturing rabbit-mouse hybridomas and monoclonal antibodies secreted by rabbit-mouse hybridomas
WO2006091326A1 (en) * 2005-01-28 2006-08-31 Attogen Inc. Anti-prl-3 antibodies and methods of use thereof
WO2011065923A1 (en) * 2009-11-30 2011-06-03 Agency For Science, Technology And Research Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008518619A (ja) * 2004-11-08 2008-06-05 エピトミクス インコーポレーティッド 抗体エンジニアリングのための方法
JP2010530735A (ja) * 2007-05-03 2010-09-16 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 細胞内のｐｒｌ−１ポリペプチドまたはｐｒｌ−３ポリペプチドに結合する抗体
JP2012505654A (ja) * 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
WO2015119570A1 (en) * 2014-02-07 2015-08-13 Agency For Science, Technology And Research Prl-3 as a biomarker for the prognosis of cancer and a target for therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRONTIERS IN BIOSCIENCE, vol. 13, JPN6018037957, 2008, pages 1619 - 1633, ISSN: 0004632667 *

Also Published As

Publication number Publication date
EP3469003A1 (en) 2019-04-17
US20200181283A1 (en) 2020-06-11
AU2017285995A1 (en) 2019-01-31
JP2022078202A (ja) 2022-05-24
KR20190024961A (ko) 2019-03-08
BR112018075901A2 (pt) 2019-03-19
JP7408707B2 (ja) 2024-01-05
WO2017217934A1 (en) 2017-12-21
SG11201811068YA (en) 2019-01-30
CA3025756A1 (en) 2017-12-21
EP3469003A4 (en) 2020-07-29
AU2017285995B2 (en) 2023-11-30
CN109476759B (zh) 2022-11-08
CN109476759A (zh) 2019-03-15
US11155636B2 (en) 2021-10-26
KR102451588B1 (ko) 2022-10-06

Similar Documents

Publication Publication Date Title
JP7755635B2 (ja) 抗ｈｅｒ２抗体
EP3212231B1 (en) Anti-tim-3 antibodies
US9062100B2 (en) Anti-human TROP-2 antibody having anti-tumor activity in vivo
US8227578B2 (en) Anti-human dlk-1 antibody showing anti-tumor activity in vivo
US8017118B2 (en) Anti-hDlk-1 antibody having an antitumor activity in vivo
KR20180114218A (ko) 항-lag-3 항체
JP2017538441A (ja) 抗ｔｉｍ−３抗体
KR20170136553A (ko) 당화 pd-l1에 특이적인 항체 및 그의 사용 방법
EA035947B1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
US11220543B2 (en) Antibody binding specifically to CD66c and use thereof
JP2020505069A (ja) ＴＧＦ−βデコイ受容体
JP7408707B2 (ja) Ｐｒｌ３抗体
US12091457B2 (en) Use for preventing and treating myeloid-derived suppressor cell-related diseases
US20200071406A1 (en) T cell receptor like antibodies
HK40006061B (en) Prl3 antibody
HK40006061A (en) Prl3 antibody
TW202342528A (zh) 抗人類ｃｘｃｌ１抗體

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200424

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210623

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211105